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Abstract
In humans, recombinant human thyrotropin (rhTSH) enhances radioactive iodine uptake (RAIU) in patients with
differentiated thyroid cancer. No studies have been performed in veterinary medicine to optimize radioiodine treatment of
thyroid cancer. The aim of this study was to evaluate the effect of rhTSH on the uptake of radioiodine-123 (123I) in dogs with
thyroid tumors. Nine dogs with thyroid neoplasia were included in this prospective cross-over study. The dogs were divided
in 2 groups. In one group, 123I was administered for a baseline RAIU determination in week 1. In week 2 (after a washout
period of 2 weeks), these dogs received rhTSH (100 mg IV) 24 h before 123I injection. In the other group the order of the
protocol was reversed. For each scan, the dogs received 37 MBq (1 mCi) of 123I intravenously (IV) and planar scintigraphy
was performed after 8 and 24 h for tumor RAIU calculation. Overall, rhTSH administration caused no statistically significant
change on thyroid tumor RAIU at 8 h (p = 0.89) or at 24 h (p = 0.98). A significant positive correlation was found between
the effect of rhTSH on tumor 8h-RAIU and rhTSH serum concentrations at 6 h (t= 0.68; p = 0.03), at 12 h (t= 0.68; p = 0.03)
and at 24 h (t= 0.78; p = 0.02) after rhTSH injection. This study suggests that IV administration of 100 mg rhTSH 24 h before
123I has an inconsistent effect on thyroid tumor RAIU. Further studies are necessary to determine the best protocol of rhTSH
administration to optimize thyroid tumor RAIU.
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Introduction
Thyroid tumors account for 10–15% of all head and neck
neoplasms in dogs [1,2]. Ninety percent of canine thyroid tumors
are carcinomas and 16–38% of the patients present evidence of
metastasis at the time of diagnosis [1,3]. Surgery is the preferred
treatment modality for mobile tumors, while large invasive tumors
have a better prognosis with external beam radiation or
radioactive iodine-131 (131I) therapy [1]. Two recent retrospective
studies showed prolonged median survival times of 27 and
30 months following 131I therapy [4,5]. Furthermore, 131I may
be the only effective therapy against thyroid cancer metastases. In
dogs, high doses of 131I are required and this usually implies a
prolonged hospitalization period and high doses of radiation
eliminated to the environment through the excreta. Use and
exposure to radiation should be kept ‘‘as low as reasonably
achievable’’ (ALARA principle) to minimize risks for patient and
human health [6]. Exposure of nonthyroidal tissues to high doses
of radiation may cause treatment complications such as fatal
myelosuppression [4,7]. Major limitations of 131I therapy include
its selected effectiveness in differentiated thyroid tumors exhibiting
adequate 131I uptake and the potential need of multiple treatments
for tumor control.
In human medicine, recombinant human thyrotropina (rhTSH,
Genzyme Corporation, Cambridge, ME, USA) is used to increase
131I uptake by normal and neoplastic thyroid tissue in the
treatment and diagnostic follow-up of differentiated thyroid
carcinoma [8]. In addition, the use of rhTSH before 131I therapy
is associated with a lower whole-body exposure to radiation,
limiting treatment complications [9].
Thyrotropin (TSH) binds to a membrane TSH G protein-
coupled receptor on the surface of follicular thyroid cells and
triggers a cascade of intracellular reactions leading to synthesis and
secretion of triiodothyronine (T3), thyroxine (T4) and thyroglob-
ulin (Tg) [10]. Prolonged TSH stimulation (.24 h) increases the
expression and functionality of the Na/I symporter (NIS) and,
consequently, leads to an increased uptake and organification of
iodine [11,12].
In veterinary medicine, rhTSH has been mainly used for the
diagnosis of canine hypothyroidism due to the lack of specificity of
the current endogenous TSH assay [13]. However, TSH receptors
have already been demonstrated in canine neoplastic thyroid cells;
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both in primary tumors and metastases [14]. The optimization of
radioiodine treatment with rhTSH may offer important clinical
advantages. On one hand, by increasing the uptake 131I by the
thyroid tumor, rhTSH may improve 131I treatment efficacy and
decrease the need for multiple treatments. On the other hand,
rhTSH may allow a decrease of the therapeutic dosage of 131I,
thereby improving radioprotection, limiting radiotoxicity and
complying with the ALARA principle. Furthermore, 131I dose
reduction could potentially reduce the required hospitalization
period and costs.
The use of 131I for diagnostic imaging in clinical research has
several limitations. Its half-life (8 days) makes it impractical for
repeated radioactive iodine uptake (RAIU) determinations within
a reasonable period. Furthermore, the emission of beta particles
during the decay of 131I causes a higher localized radiation dose
and may have a deleterious effect on the uptake of the actual 131I
therapeutic dosage, a phenomenon named thyroid stunning [15].
Unlike 131I, 123I has a much shorter half-life (13 h), decays by
emitting gamma rays and has been shown to be equal or even
superior to 131I as a scanning agent [16]. Hence, in this study 123I
was chosen as an imaging agent, despite its high cost. Recent pilot
studies performed by our group have already investigated the use
of rhTSH to optimize the uptake of radioiodine-123 (123I) in
healthy dogs and hyperthyroid cats [17,18]. The goal of this study
was to evaluate the effect of 100 mg rhTSH, administered IV 24 h
before 123I, on tumor RAIU in dogs with thyroid tumors.
Materials and Methods
Sample size
A preliminary power analysis showed that 9 patients included in
a prospective cross-over study would suffice to detect a 28%
increase in tumor RAIU with a power of 80% at a global
significance level of 5%.
Animals
The inclusion criteria of our study were diagnosis of thyroid
neoplasia by either cytology, biopsy and/or scintigraphy and
tumor uptake of 123I at scintigraphy. Patients where treatment was
deemed urgent due to upper airway obstruction were excluded.
The first nine dogs referred to the Small Animal Clinic of Ghent
University that met the inclusion criteria and for which owner
consent was obtained, were included. Patients were recruited
between December 2007 and November 2011. Diagnosis was
based on physical examination, cervical mass cytology, cervical
scintigraphy and, when available, histopathology. Complete
hematological and biochemical analysis, including serum total
thyroxine (TT4) and TSH, were performed in all patients.
Determination of thyroid functional status was based on clinical
signs, basal serum TT4 and TSH concentrations, cervical
scintigraphy and TSH stimulation. Results of TSH stimulation
were interpreted comparing serum TT4 concentrations at baseline
and 6 h after rhTSH administration. Euthyroidism was confirmed
when post-stimulation TT4 was$40 nmol/L and hypothyroidism
was considered likely when post-stimulation TT4 concentration
was ,20 nmol/L [13,19]. Intermediate results (post-stimulation
TT4 between 20 and 40 nmol/L) were not observed.
All dogs were staged according to the WHO staging system for
canine thyroid tumors [20]. For this purpose, cervical palpation,
tridimensional measurement of the tumor, radiographs or
computed tomography (CT) of the thorax, cervical and thoracic
scintigraphy were performed in all patients. Cervical ultrasound
was performed in 6 patients. Cervical and thoracic computed
tomography was performed in 4 patients. Abdominal ultrasound
was performed in 2 patients.
During the washout period, the dogs stayed at home. Diet and
water source were kept unchanged during the study.
Ethics statement
Animal care was in accordance with European guidelines and
directives (EC directive 86/609/EEC for animal experiments) and
the study was approved by the Ethical committee of the Faculty of
Veterinary Medicine of Ghent University and by the Belgian
Deontological committee (approval number EC 2010/168).
Furthermore, an owner consent form was signed by all owners.
Study design
The dogs were divided in 2 groups in a prospective cross-over
study. In group A, 123I was administered for a baseline RAIU
determination in week 1. In week 2 (after a washout period of
2 weeks), these dogs received rhTSH (100 mg IV) 24 h before 123I
injection. In group B the order of the protocol was reversed
(Table 1). For each scan, the dogs received 37 MBq (1mCi) of 123I
IV and planar scintigraphy was subsequently performed at 8 h
and 24 h for tumor RAIU calculation.
Blood samples
Blood samples were taken for serial measurements of TT4 and
rhTSH serum concentrations in the week rhTSH was adminis-
tered. Blood was collected by jugular venipuncture at baseline, 6,
12, 24 and 48 h after rhTSH injection. Blood was centrifuged and
the serum was stored for at least 3 weeks at 220uC to reach
sufficient decay of radioactivity to be analyzed.
The TT4 serum concentration was determined with a
commercially available solid-phase, chemiluminescent competitive
immunoassay (IMMULITE 2000 Canine Total T4, Siemens,
Deerfield, IL, USA) previously validated in dogs, and the reference
range used was 6.45–43.86 nmol/L [21]. Basal TSH serum
concentration was determined with a commercially available solid-
phase, two-site chemiluminescent immunometric assay (IMMU-
LITE 2000 Canine TSH, Siemens, Deerfield, IL, USA) previously
validated in dogs, and the reference range used was ,0.5 ng/mL
[21].
rhTSH serum concentrations were measured with a commer-
cially available chemiluminescent microparticle immunoassay for
human TSH determination in an immunoassay analyzer (Abbott
ARCHITECT i2000SR, Abbott Laboratories, Abbott Park, IL,
USA) [22].
Recombinant human TSH
Each vial of 900 mg of rhTSH was reconstituted with 4.5 mL of
sterile water (200 mg/mL). Individual doses of 100 mg of freshly
reconstituted rhTSH were prepared in 1 mL plastic syringes with
needle and rubber caps and were stored frozen at 220uC for a
maximum of 12 weeks [13,23]. For TSH stimulation, frozen
rhTSH was thawed at room temperature a few minutes before
administration.
RAIU
Each dog received 37 MBq (1 mCi) of 123I IV. The injected
activity of 123I was calculated by subtracting the activity of the
empty syringe from the activity of the full syringe both measured in
a dose calibrator. To determine the tumor/metastases RAIU, a
static planar ventrodorsal image was obtained with a one head c-
camera (Toshiba GCA 901) using a low-energy high resolution
collimator with the dog in sternal recumbency under general
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anesthesia. General anesthesia was induced with propofol and
maintained with isoflurane vaporized in oxygen using a rebreath-
ing system. Data were acquired during 5 minutes for the 8 h-
RAIU and 10 minutes for the 24 h-RAIU on a 1286128 matrix.
A syringe with a known amount of radioactivity (2.561.6 MBq)
was placed next to the animal and served as the standard activity
necessary to calculate the RAIU. Regions of interest (ROI) were
manually drawn over the primary tumor/metastases and over the
activity of the standard [24]. In order to correct for background
activity a ROI with the same dimensions as the ROI over the
tumor was drawn over an area close to, but not overlapping, the
thyroid tumor (soft tissue background correction) and another
ROI with the same dimensions of the ROI over the standard was
placed outside the dog (room background correction). The total
number of counts in each ROI was recorded and transformed to
counts per minute (cpm) for RAIU calculation, yielding cpmtumor,
cpmstandard, cpmbackground and cpmroom. These ROI’s were placed
on one day and by the same person (EV). RAIU was calculated as
a percentage of the administered dose of 123I corrected for physical
decay and background activity using the following formula:
cpmtumorcpmbackground
 
= cpmstandardcpmroomð Þ
h i
|
MBqstandard=MBqinjectedactivity
 
|100
Statistical analysis
Data were analyzed with SAS version 9.1 (SAS, Cary, North
Carolina, USA). The effect of rhTSH administration on RAIU
was analyzed with a mixed model with period, treatment, time and
the interaction between treatment and time as categorical fixed
effects and dog and the period by dog interaction as random
effects. Comparisons were based on the F-test at a global
significance level of 5%, using Tukey’s procedure for multiple
comparisons.
The change of TT4 serum concentration from baseline to 6 h
was analyzed using a mixed model with dog as random effect and
time as a categorical fixed effect.
Possible associations between the effect of rhTSH on tumor
RAIU (at either 8 h or 24 h) and rhTSH serum concentration at
all time points and results of TSH stimulation were evaluated with
the Kendall’s t correlation coefficient.
The association between the effect of rhTSH on tumor RAIU
(at either 8 h or 24 h) and thyroid function status (euthyroid vs
hyperthyroid) was evaluated on a data set excluding the one
hypothyroid patient that was in the data set. The analysis was
based on a mixed model with period, treatment, time, status and
the interactions between treatment, time and status as categorical
fixed effects and the dog and the period by dog interaction as
random effects.
Results
Two mixed breed dogs, 1 medium-sized Poodle, 1 American
Staffordshire Terrier, 1 German Longhaired Pointer, 1 Jack
Russell Terrier, 1 Bearded Collie, 1 Belgian Shepherd Malinois
and 1 Beagle were included in this study. Six dogs were males, 3
were females, mean age was 9.5 years (range 6–12 years).
Six dogs were diagnosed with unilateral thyroid tumors, 1 dog
had bilateral thyroid tumors and 2 dogs had ectopic tumors. Three
patients were diagnosed with thoracic metastases visible at
scintigraphy (n= 2) and radiographs (n = 1). Histopathology was
performed in 6 patients. The only patient for which cytology or
histopathology were not performed was diagnosed with an ectopic
thyroid tumor clearly visible at scintigraphy. Furthermore, the dog
had clinical hyperthyroidism.
Five dogs were euthyroid, 3 dogs were hyperthyroid and 1 dog
was hypothyroid. All patients presented for a palpable cervical
mass. Additionally, the 3 hyperthyroid dogs presented with PU/
PD and weight loss; two of these also presented polyphagia. The
hypothyroid dog had been diagnosed several years prior to referral
and was being treated with levothyroxine supplementation. One
dog had been previously diagnosed and treated for hypothyroid-
ism but was reclassified as euthyroid based on basal TT4 serum
concentrations, cervical scintigraphy and TSH stimulation results
at the moment of inclusion in our study. In both cases,
levothyroxine supplementation was interrupted for at least 3 days
before the study week. Four patients were diagnosed with stage II,
Table 1. Thyroid function status, tumor histopathology, primary tumor RAIU and cross-over group in 9 dogs with thyroid tumors.
Dog Thyroid function Histopathology
8h RAIU
(%)
8h-rhTSH RAIU
(%)
24h RAIU
(%)
24h-rhTSH RAIU
(%) Group
1 Euthyroid Compact carcinoma 8,5 7,8 17,4 15,7 A
2 Euthyroid Compact carcinoma 0,2 0,8 0,2 0,6 A
3 Euthyroid Follicular-papillary carcinoma 3,1 3,7 4,9 8,3 A
4 Hyperthyroid Compact carcinoma 10,6 16,2 27,2 14,8 A
5 Hyperthyroid Follicular-compact carcinoma 8,9 7,0 10,7 9,9 A
6 Euthyroid NA 3,4 9,3 5,6 13,7 A
7 Hyperthyroid NA 29,6 29,5 31,1 28,3 B
8 Euthyroid C-cell carcinoma 0,7 2,0 0,9 2,8 B
9R Hypothyroid NA 2,1 1,7 1,8 1,6 B
9L NA 0,8 0,4 0,7 0,5 B
Mean 6Std Dev 6,868,9 7,869,0 10,0611,4 9,668,9
The mean and standard deviation of the 8 h- and 24 h-RAIU with and without rhTSH stimulation are given.
NA: not available; R: right; L: left.
doi:10.1371/journal.pone.0050344.t001
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2 patients with stage III and 3 patients with stage IV thyroid
cancer.
The results of thyroid function status, tumor histopathology and
tumor RAIU determination of each dog are summarized in
Table 1. After rhTSH administration, the 8 h-RAIU increased in
5 tumors and the 24 h-RAIU increased in 4 tumors. Overall,
rhTSH caused no statistically significant change on primary
thyroid tumor RAIU at 8 h (p = 0.89) or at 24 h (p= 0.98)
(Figure 1). The RAIU of thoracic metastases could only be
evaluated in 2 of the 3 patients with stage IV disease. After rhTSH
administration, the 8 h- and 24 h-RAIU increased in 1 thoracic
metastasis (Table 2).
TT4 and rhTSH serum concentrations were measured imme-
diately before and followed up after rhTSH injection in 4
euthyroid dogs, 1 hyperthyroid dog and 1 hypothyroid dog. The
4 euthyroid patients showed a significant increase in TT4 serum
concentrations 6 h after rhTSH injection compared to baseline
(p = 0.01) (Table 3). The hyperthyroid dog and the hypothyroid
dog did not show meaningful changes in serum TT4 concentra-
tions at any time point.
A significant positive correlation was found between the effect of
rhTSH on tumor 8 h-RAIU and rhTSH serum concentrations at
6 h (t=0.68; p = 0.03), at 12 h (t=0.68; p = 0.03) and at 24 h
(t=0.78; p = 0.02) after rhTSH injection. When tumor metastases
were included in the analysis, a significant positive correlation was
also detected between the effect of rhTSH on 24 h-RAIU and
rhTSH serum concentrations at 6 h (t=0.59; p = 0.04), 24 h
(t=0.59; p = 0.04) and 48 h (t=0.67; p= 0.02). No significant
correlation was found between the change in TT4 serum
concentrations from baseline to 6 h and the effect of rhTSH on
tumor RAIU, at either 8 h (p = 0.54) or 24 h (p = 0.13).
Hyperthyroid dogs had significantly higher RAIU values than
euthyroid dogs (p = 0.01). Furthermore, the effect of the rhTSH on
24 h-RAIU differed significantly between euthyroid and hyper-
thyroid dogs (p = 0.02) but not at 8 h (p = 0.98). In euthyroid dogs,
the 24 h-RAIU increased from 5.8%, at baseline, to 8.2%, after
rhTSH. In hyperthyroid dogs, the 24 h-RAIU decreased from
23%, at baseline, to 17.7%, after rhTSH.
No adverse effects were observed following the administration of
rhTSH.
Discussion
Thyroid cancer is the most common endocrine neoplasia in
dogs and, as in humans, these tumors are mainly of follicular cell
origin [1]. In humans, rhTSH stimulates the uptake of 131I in
patients with differentiated thyroid carcinoma and can be used to
improve the efficacy of 131I therapy [25]. Additionally, the use of
rhTSH before 131I therapy is associated with a lower 131I effective
half-life and, consequentely, lower exposure of blood and the
whole-body to radiation. This limits radiotoxicity without com-
promising the efficacy of the treatment [9]. The obvious benefits of
the use of rhTSH to optimize the treatment of human thyroid
cancer with 131I provides an interesting perspective for the
optimization of 131I therapy of canine thyroid tumors. Increased
131I uptake by canine thyroid tumors may improve treatment
efficacy and decrease the need for multiple treatments; reduced
blood exposure to radiation may limit myelossupression; 131I dose
reduction could improve radioprotection, reduce the hospitaliza-
tion period and costs. This is the first study to evaluate the effect of
rhTSH on radioiodine uptake in dogs with thyroid tumors.
Overall, no significant effect of rhTSH on tumor RAIU was
observed with our protocol. These results are in agreement with
the results of a recent pilot study performed by our group in
healthy Beagles [17]. In that study, rhTSH (100 mg IV,
administered 24 h or 48 h before 123I) also did not cause a
significant change in thyroid RAIU. Earlier reports have suggested
the potential of exogenous TSH to increase thyroid RAIU in dogs
[26,27,28]. However, in these studies the effect of TSH stimulation
on thyroid 131I uptake was described in a small number of healthy
and hypophysectomized dogs and no statistical analysis was
performed. In healthy humans, TSH stimulation with a protocol
similar to the one used in this study was shown to approximately
double thyroid RAIU [29].
The inconsistent effect of rhTSH on thyroid tumor RAIU
observed in our study raises important issues regarding the dosage,
the route and timing of rhTSH administration. The significant
increase in TT4 serum concentrations 6 h after rhTSH injection,
observed in euthyroid patients, was expected and confirmed the
biological activity of rhTSH. The observed correlation between
the effect of rhTSH on tumor RAIU and rhTSH serum
concentrations suggests that higher plasma concentrations of
rhTSH may allow an increased uptake of 123I by thyroid tumors.
The plasma concentration of rhTSH at different time points is
mainly related to the dose administered. It is possible that doses
higher than 100 mg may induce a more consistent increase of
thyroid tumor RAIU. In humans, high plasma concentrations of
TSH (.30 mIU/mL) are deemed necessary to stimulate sodium-
iodide symporters to concentrate iodine, in normal and neoplastic
thyroid tissue. Hence, high doses of rhTSH (26900 mg IM 24 h
apart) are administered 24 h before 131I injection for diagnostic
follow-up and treatment of differentiated thyroid cancer. Never-
theless, the optimal magnitude of TSH elevation is unknown and
Figure 1. Primary thyroid tumor RAIU in 9 dogs with thyroid
tumors. The mean and standard deviation of the 8 h- and 24 h-RAIU
with and without rhTSH stimulation are given.
doi:10.1371/journal.pone.0050344.g001
Table 2. Thyroid function status, metastases RAIU and cross-over group in 2 dogs with thoracic metastases.
Dog Thyroid function 8h RAIU (%) 8h-rhTSH RAIU (%) 24h RAIU (%) 24h-rhTSH RAIU (%) Group
3 – thorax Euthyroid 0.05 0.15 0.04 0.09 A
8 – thorax Euthyroid 0.03 0.01 0.06 0.01 B
doi:10.1371/journal.pone.0050344.t002
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differs among patients [30]. It is interesting to note that, in our
study, all patients with rhTSH serum concentrations .30 mIU/
mL 6 h after rhTSH injection experienced an increase in thyroid
tumor RAIU after rhTSH. The administration of rhTSH doses
similar to those given to humans with thyroid cancer is not realistic
in the veterinary clinical setting given the high cost of rhTSH.
Furthermore, studies in humans with multinodular goiter have
demonstrated that rhTSH doses as low as 5 or 100 mg suffice to
effectively increase thyroid RAIU [31]. In our study, the dosage of
100 mg was chosen because this dose is considered appropriate for
a functional stimulation of the thyroid gland in most dogs [13].
Further studies are necessary to determine the effect of higher
doses of rhTSH on thyroid tumor RAIU in dogs.
An important factor influencing the pharmacokinetics of
rhTSH is the route of administration. In our study, the IV route
was chosen to maximize bioavailability. Although there are no
reports arguing that the IM route is preferable, it is possible that if
rhTSH is administered IM, such as in humans, its clearance is
slower allowing a longer stimulation of the thyroid cells and
possibly increasing tumor RAIU more consistently.
In our study, rhTSH was administered 24 h before 123I because
studies on FRTL-5 cells (Fischer rat thyroid cell line) revealed that
12 to 24 h are needed before TSH stimulates accumulation of
iodine in thyroid cells and because this is considered the optimal
timing to increase thyroid RAIU in humans [11,32]. The optimal
timing of rhTSH administration to increase thyroid RAIU in dogs
with thyroid tumors is currently unknown.
The inconsistent effect of rhTSH on thyroid tumor RAIU may
not be related to the protocol of rhTSH administration but rather
to intrinsic properties of the neoplastic thyroid tissue. It has been
shown that the concentration and affinity of TSH receptors in
neoplastic canine thyroid cells is variable [14]. Indeed, 8 of 22
primary canine thyroid tumors were shown to have fewer TSH-
binding sites than the lowest value observed in normal thyroid
tissues. That study suggested that TSH receptor concentration
could be related to the functional variability of thyroid neoplasms.
Likewise, studies in humans have demonstrated that the expression
of TSH-receptor mRNA may be decreased in thyroid carcinomas
[33]. Additionally, in vitro studies have revealed that TSH
unresponsiveness in human thyroid carcinomas can also be
related to defects in TSH signal transduction or errors in iodine
transport [34,35].
As expected, our study showed that hyperthyroid dogs had
significantly higher RAIU values than euthyroid dogs. In
hyperthyroidism, increased thyroid function enhances iodine
trapping and organification. Hence, dogs with thyroid tumors
and hyperthyroidism frequently present high tumoral 131I uptake
and are often ideal candidates for 131I therapy [36]. The
significantly different effect of rhTSH on thyroid RAIU between
euthyroid and hyperthyroid patients was an interesting finding. In
a study of 55 dogs with thyroid tumors, dogs with evidence of
autonomous hyperfunction of the goiter had an increased
thyroidal iodine turn-over [28]. It is possible that a positive effect
of rhTSH on tumor RAIU occurs sooner in hyperthyroid patients
and was, therefore, not observed with our protocol (RAIU
determination 8 h and 24 h after 123I injection). On the other
hand, the lack of effect of rhTSH in hyperthyroid patients may be
caused by decreased thyroid functional reserve. This seems,
however, less likely because in hyperthyroid cats and in humans
with toxic nodular goiter (a condition characterized by nodular
enlargement of the thyroid gland and hyperthyroidism), a
significant increase in thyroid RAIU is observed after rhTSH
administration [18,37].
The administration of rhTSH to patients with thyroid
carcinoma raises important safety issues. In humans, rhTSH
causes expansion of primary thyroid tumors and thyroid tumor
metastases [38,39]. Therefore, rhTSH should be used carefully in
patients with large thyroid tumors or central nervous system,
spinal, lung or bone metastases. A pilot study performed in healthy
Beagles showed no effect of rhTSH on thyroid gland volume [40].
Likewise, no adverse effects of rhTSH were observed during our
study.
All thyroid tumors for which histopathology was available were
malignant and 5 of the 6 tumors were of follicular cell origin. This
was expected as 90% of canine thyroid tumors are malignant and
only patients with 123I uptake were included [1]. In humans and
dogs, malignant thyroid tumors are predominantly of follicular cell
origin, but in humans only 8.1–14.8% of all thyroid nodules are
malignant [41]. Another important difference resides in the
predominant histologic types. In dogs, thyroid carcinomas are
predominantly mixed follicular-compact, while in humans 80% of
thyroid malignancies are of papillary type which is rare in dogs
[42,43]. Undifferentiated carcinomas are relatively uncommon in
both species, accounting for 2% of thyroid malignancies in
humans and 12% in dogs.
One dog with a C-cell carcinoma presented 123I uptake by the
primary tumor and thoracic metastases. To the authors knowl-
edge, there is only one previous report in veterinary medicine and
very limited reports in human medicine of medullary carcinomas
exhibiting iodine uptake [36,44,45]. The mechanism underlying
the ability of medullary carcinoma cells to trap iodine remains
unclear.
In conclusion, our study shows that 100 mg rhTSH adminis-
tered IV 24 h before 123I has no significant effect on thyroid tumor
RAIU in dogs. The detected correlation between increased tumor
RAIU and rhTSH serum concentrations attained after injection
suggests that higher dosages of rhTSH may be necessary. Further
studies are needed to determine the optimal protocol of rhTSH
administration to increase thyroid tumor RAIU in dogs.
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Table 3. rhTSH and TT4 serum concentrations in dogs with
thyroid tumors before and after injection of 100 mg rhTSH IV.
Time point rhTSH (mIU/L) TT4 (nmol/L)
Baseline 0 (0) 24.2 (6.45)
6 h 26.97 (4.47) 50.97 (7.03)
12h 9.52 (1.45) 35.79 (10.47)
24 h 3.30 (0.63) 25.83 (9.1)
48 h 0.77 (0.27) 22.28 (6.94)
The mean values (standard deviation) of rhTSH serum concentrations of 6 dogs
and TT4 serum concentrations of 4 euthyroid dogs with thyroid tumors are
given for each time point.
doi:10.1371/journal.pone.0050344.t003
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